CampestanolCAS# 474-60-2 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 474-60-2 | SDF | Download SDF |
PubChem ID | 119394 | Appearance | Powder |
Formula | C28H50O | M.Wt | 402.70 |
Type of Compound | Steroids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (3S,5S,8R,9S,10S,13R,14S,17R)-17-[(2R,5R)-5,6-dimethylheptan-2-yl]-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol | ||
SMILES | CC(C)C(C)CCC(C)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)O)C)C | ||
Standard InChIKey | ARYTXMNEANMLMU-ATEDBJNTSA-N | ||
Standard InChI | InChI=1S/C28H50O/c1-18(2)19(3)7-8-20(4)24-11-12-25-23-10-9-21-17-22(29)13-15-27(21,5)26(23)14-16-28(24,25)6/h18-26,29H,7-17H2,1-6H3/t19-,20-,21+,22+,23+,24-,25+,26+,27+,28-/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Campestanol, which shares the same basic structure and intestinal absorption pathway with cholesterol, does not accumulate when fed, and may be incorporated into the diet to block cholesterol absorption. |
Campestanol Dilution Calculator
Campestanol Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.4832 mL | 12.4162 mL | 24.8324 mL | 49.6648 mL | 62.081 mL |
5 mM | 0.4966 mL | 2.4832 mL | 4.9665 mL | 9.933 mL | 12.4162 mL |
10 mM | 0.2483 mL | 1.2416 mL | 2.4832 mL | 4.9665 mL | 6.2081 mL |
50 mM | 0.0497 mL | 0.2483 mL | 0.4966 mL | 0.9933 mL | 1.2416 mL |
100 mM | 0.0248 mL | 0.1242 mL | 0.2483 mL | 0.4966 mL | 0.6208 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Daucosterol
Catalog No.:BCN5531
CAS No.:474-58-8
- Reserpin N-oxide
Catalog No.:BCN3493
CAS No.:474-48-6
- Citrostadienol
Catalog No.:BCN7357
CAS No.:474-40-8
- Chenodeoxycholic acid
Catalog No.:BCN2620
CAS No.:474-25-9
- Brazilin
Catalog No.:BCN5529
CAS No.:474-07-7
- Forskolin G
Catalog No.:BCN5527
CAS No.:473981-11-2
- Lersivirine
Catalog No.:BCC1698
CAS No.:473921-12-9
- Boc-Tyr(tBu)-OH
Catalog No.:BCC3462
CAS No.:47375-34-8
- SCH 563705
Catalog No.:BCC1933
CAS No.:473728-58-4
- SCH 527123
Catalog No.:BCC1932
CAS No.:473727-83-2
- AMG 487
Catalog No.:BCC5140
CAS No.:473719-41-4
- Boc-Trp(For)-OH
Catalog No.:BCC3456
CAS No.:47355-10-2
- Campesterol
Catalog No.:BCN3181
CAS No.:474-62-4
- Brassicasterol
Catalog No.:BCN2613
CAS No.:474-67-9
- CAL-130 Racemate
Catalog No.:BCC1442
CAS No.:474012-90-3
- N-Methylsarpagine methosalt
Catalog No.:BCN5530
CAS No.:47418-70-2
- Monomethyl auristatin E
Catalog No.:BCC1775
CAS No.:474645-27-7
- 2,16-Kauranediol 2-O-beta-D-allopyranoside
Catalog No.:BCN1436
CAS No.:474893-07-7
- ST 91
Catalog No.:BCC7436
CAS No.:4749-61-5
- SB 657510
Catalog No.:BCC7713
CAS No.:474960-44-6
- H-N-Me-Pro-OH
Catalog No.:BCC3351
CAS No.:475-11-6
- (+)-Isocorynoline
Catalog No.:BCN2361
CAS No.:475-67-2
- Liriodenine
Catalog No.:BCN5532
CAS No.:475-75-2
- Aristolochic acid B
Catalog No.:BCN6263
CAS No.:475-80-9
Dietary sitostanol and campestanol: accumulation in the blood of humans with sitosterolemia and xanthomatosis and in rat tissues.[Pubmed:16331855]
Lipids. 2005 Sep;40(9):919-23.
Dietary sitostanol has a hypocholesterolemic effect because it decreases the absorption of cholesterol. However, its effects on the sitostanol concentrations in the blood and tissues are relatively unknown, especially in patients with sitosterolemia and xanthomatosis. These patients hyperabsorb all sterols and fail to excrete ingested sitosterol and other plant sterols as normal people do. The goal of the present study was to examine the absorbability of dietary sitostanol in humans and animals and its potential long-term effect. Two patients with sitosterolemia were fed the margarine Benecol (McNeill Nutritionals, Ft. Washington, PA), which is enriched in sitostanol and Campestanol, for 7-18 wk. Their plasma cholesterol levels decreased from 180 to 167 mg/dL and 153 to 113 mg/dL, respectively. Campesterol and sitosterol also decreased. However, their plasma sitostanol levels increased from 1.6 to 10.1 mg/dL and from 2.8 to 7.9 mg/dL, respectively. Plasma Campestanol also increased. After Benecol withdrawal, the decline in plasma of both sitostanol and Campestanol was very sluggish. In an animal study, two groups of rats were fed high-cholesterol diets with and without sitostanol for 4 wk. As expected, plasma and liver cholesterol levels decreased 18 and 53%, respectively. The sitostanol in plasma increased fourfold, and sitostanol increased threefold in skeletal muscle and twofold in heart muscle. Campestanol also increased significantly in both plasma and tissues. Our data indicate that dietary sitostanol and Campestanol are absorbed by patients with sitosterolemia and xanthomatosis and also by rats. The absorbed plant stanols were deposited in rat tissues. Once absorbed by sitosterolemic patients, the prolonged retention of sitostanol and Campestanol in plasma might increase their atherogenic potential.
Hyperabsorption and retention of campestanol in a sitosterolemic homozygote: comparison with her mother and three control subjects.[Pubmed:11060358]
J Lipid Res. 2000 Nov;41(11):1883-9.
We measured the percent absorption, turnover, and distribution of Campestanol (24-methyl-5alpha-cholestan-3beta-ol) in a sitosterolemic homozygote, her obligate heterozygous mother, and three healthy human control subjects. For reasons relating to sterol hyperabsorption, the homozygote consumed a diet low in plant sterols that contained Campestanol at about 2 mg/day. The heterozygote and three control subjects were fed a diet supplemented with a spread that contained Campestanol at 540 mg/day and sitostanol (24-ethyl-5alpha-cholestan-3beta-ol) at 1.9 g/day as fatty acid esters. Plasma Campestanol concentrations determined by capillary gas-liquid chromatography were 0.72 +/- 0.03 mg/dl in the homozygote, 0.09 +/- 0.04 mg/dl in the heterozygote, and 0.05 +/- 0.03 mg/dl for the control mean. After simultaneous pulse labeling with [3alpha-(3)H]Campestanol intravenously and [23-(14)C]Campestanol orally, the maximum percent absorption measured by the plasma dual-isotope ratio method as a single time point was 80% in the homozygote, 14.3% in the heterozygote, and 5.5 +/- 4.3% as the mean for three control subjects. Turnover (pool size) values estimated by mathematical analysis of the specific activity versus time [3alpha-(3)H]Campestanol decay curves were as follows: 261 mg in the homozygote, 27.3 mg in the heterozygote, and 12.8 +/- 7.6 mg in the three control subjects (homogygote vs. controls, P < 0.001). The calculated production rate (mg/24 h) equivalent to actual absorption in the presence of dietary sterols and stanols was 0.67 mg/day or 31% of intake in the homozygote, 2.1 mg/day or 0.3% of intake in the heterozygote, and 0.7 +/- 0.3 mg/day or 0.1% of intake in the three control subjects. However, the excretion constant from pool A (K(A)) was prolonged markedly in the homozygote, but was 100 times more rapid in the heterozygote and three control subjects.Thus, Campestanol, like other noncholesterol sterols, is hyperabsorbed and retained in sitosterolemic homozygotes. However, Campestanol absorption was only slightly increased in the sitosterolemic heterozygote and removal was as rapid as in control subjects.
Campestanol (24-methyl-5alpha-cholestan-3beta-ol) absorption and distribution in New Zealand White rabbits: effect of dietary sitostanol.[Pubmed:10094114]
Metabolism. 1999 Mar;48(3):363-8.
Campestanol (24-methyl-5alpha-cholestan-3beta-ol) is a naturally occurring plant stanol, structurally similar to cholesterol (5-cholesten-3beta-ol) and widely distributed in vegetable oils consumed in human diets. We measured the absorption and turnover of Campestanol by the plasma dual-isotope ratio method and mathematical analysis of specific activity versus time decay curves after simultaneous oral and intravenous pulse-labeling with [3alpha-3H]- and [23-14C]-labeled Campestanol, respectively, in New Zealand White (NZW) rabbits: six fed chow and six fed chow with 125 mg/d Campestanol and 175 mg/d sitostanol (24-ethyl-5alpha-cholestan-3beta-ol). Plasma concentrations increased insignificantly from 0.08+/-0.01 to 0.09+/-0.01 mg/dL with dietary stanols. The percent Campestanol absorption measured by the plasma dual-isotope ratio method after the rabbits were fasted for 6 hours yielded the percent absorption in the absence of competing intestinal sterols and stanols and declined insignificantly from 11.6%+/-3.5% in controls to 8.1%+/-3.7% in the treated rabbit groups. In contrast, the turnover, which measured actual absorption averaged over 24 hours, increased from 0.12+/-0.05 to 0.37+/-0.05 mg/d (P < .05) with Campestanol and sitostanol added to the diet. However, the actual percent absorption declined from 3% to 0.3% of dietary intake with the Campestanol and sitostanol-enriched diet. Campestanol pool sizes, although remaining small, increased slightly from 1.1+/-0.4 to 2.5+/-1.5 mg. The removal constant (KA) from pool A (MA) did not change significantly with added dietary Campestanol and sitostanol (KA= -0.040+/-0.005 v -0.037+/-0.007 d(-1)). The results demonstrate small Campestanol plasma concentrations and body pools even when the rabbits consumed substantial amounts because (1) intestinal absorption was limited and (2) was further reduced by competing dietary sitostanol, and (3) Campestanol was removed rapidly from the body. Thus, Campestanol, which shares the same basic structure and intestinal absorption pathway with cholesterol, does not accumulate when fed, and may be incorporated into the diet to block cholesterol absorption.